108.71 +0.02 (0.02%)
Pre-market: 5:27AM EST
|Bid||107.51 x 1200|
|Ask||109.88 x 1100|
|Day's range||105.60 - 109.44|
|52-week range||62.55 - 113.41|
|Beta (5Y monthly)||0.81|
|PE ratio (TTM)||39.96|
|Forward dividend & yield||5.20 (4.78%)|
|Ex-dividend date||14 Apr 2021|
|1y target est||N/A|
Regeneron Pharmaceuticals (NASDAQ: REGN) and AbbVie (NYSE: ABBV) have managed to deliver strong fourth quarter earnings. Regeneron Pharmaceuticals' fiscal 2020 performance has been quite remarkable, considering the many pressures it faced due to COVID-19 related restrictions. Regeneron's blockbuster retinal disease drug, EYLEA, continues to be a force to reckon with, clocking sales of $7.9 billion globally (in conjucnction with Bayer).
Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) submitted its 13F-HR regulatory filing to the U.S. Securities and Exchange Commission (SEC) last week. Its activity featured new positions in four stocks and adding to positions in six stocks, including AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Buffett just bought these two dirt-cheap stocks.
Income investors should consider these three high-yield dividend stocks that the market is overlooking right now.